Cite
HARVARD Citation
Loverix, L. et al. (n.d.). 2022-RA-1473-ESGO Randomized phase II CLIO study on olaparib monotherapy versus chemotherapy in recurrent ovarian cancer – results of the Leuven HRD test. International journal of gynecological cancer. pp. A340-A341. [Online].